Skip to content

cerebellar ataxia treatment with mesenchymal stem cells

Evaluation of safety and motivation status of patients with cerebellar ataxia after intrathecal treatment with mesenchymal stem cells

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
IRCT
Registry ID
IRCT20160809029275N3
Enrollment
20
Registered
2022-08-31
Start date
2021-07-23
Completion date
Unknown
Last updated
2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diagnosis Code G32.81: Cerebellar ataxia. Cerebellar ataxia in diseases classified elsewhere

Interventions

Intervention 1: Intervention group: Patients receiving 50-70 million autologous MSCs derived from bone marrow. Intervention 2: Control group: Control group: patients with cerebellar ataxia who will re

Sponsors

Mashhad University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
10 Years to 65 Years

Inclusion criteria

Inclusion criteria: Does not receive stem cells in the last 6 months. signing the written consent form by the participants. The age range of 10-65 years without limitation in sex. Definitive diagnosis of ataxia based on brain and cervical spinal cord MRI. Presence of cerebellar or brainstem atrophy and/or cervical spinal cord. Not having other mental illness such as schizophrenia etc.

Exclusion criteria

Exclusion criteria: Positive pregnancy test. Heart, kidney and liver failure, epilepsy, lung disease, cardiac arrhythmia, diabetes, leukemia and other diseases of the central nervous system such as Parkinson's. If the total level of bilirubin is greater than 1.5 times the upper limit of its normal value. History of chronic or acute alcohol consumption The presence of evidence of seizures in the brain scan Any evidence of infection History of severe drug sensitivity or anaphylaxis to two or more foods or drugs Other organic brain diseases HIV positive and tumor markers positive Patients with severe psychosis, cognitive disorders and inability to understand or sign consent Other organic or systemic diseases Uncontrollable high blood pressure Participation in other clinical trials in the last three months The presence of thyroid disease Presence of evidence of encephalitis Presence of sarcoidosis and Behcet's disease Vitamin E deficiency Wilson's disease Increased blood ammonia Positive anti-GAD and anti-neuronal antibodies Lupus and Wegener's disease Middle ear dysfunction

Design outcomes

Primary

MeasureTime frame
Neurologic sign of patients including: Scale for the Assessment and Rating of Ataxia (SARA)-Quality of life-Depression-Beck Scale-Improve in international Co-Operative Ataxia Rating Scale-Balance Test-Tremor Rating Scale. Timepoint: Before the intervention, month 3 and month 6 after the intervention. Method of measurement: Clinical examination and questionnaire.;Blood markers including: • T4 and TSH• Alpha-fetoprotein• IgG and IgE• OGTT and FBS• ACE• Vitamin E• Electrophoresis of serum proteins• Chol, TG, LDL and HDL• Ceruloplasmin, Cu and 24-hour urine Cu for patients less than 40 years old• Anti-GAD, Anti-dsDNA, P-ANCA and C-ANCA• Vitamin B12 and folic acid. Timepoint: Before the intervention, month 3 and month 6 after the intervention. Method of measurement: Laboratory methods such as electrophoresis, VIDAS and ELISA.;Investigating the safety of stem cell treatment in patients participating in the study. Timepoint: 24-48 hours after receiving injections and the third and sixth months. Method of measurement: Clinical examination of patients to check for fever, headache or any possible allergic reactions.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Amir Reza Boroumand

Mashhad University of Medical Sciences

boroumandar@mums.ac.ir+98 51 3848 2194

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jul 12, 2026